Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23


A Genomic Profile of Local Immunity in the Melanoma Microenvironment Following Treatment with α Particle-Emitting Ultrasmall Silica Nanoparticles.

Urbanska AM, Khanin R, Alidori S, Wong S, Mello BP, Almeida BA, Chen F, Ma K, Turker MZ, Korontsvit T, Scheinberg DA, Zanzonico PB, Wiesner U, Bradbury MS, Quinn TP, McDevitt MR.

Cancer Biother Radiopharm. 2020 Feb 3. doi: 10.1089/cbr.2019.3150. [Epub ahead of print]


ALK and RET Inhibitors Promote HLA Class I Antigen Presentation and Unmask New Antigens within the Tumor Immunopeptidome.

Oh CY, Klatt MG, Bourne C, Dao T, Dacek MM, Brea EJ, Mun SS, Chang AY, Korontsvit T, Scheinberg DA.

Cancer Immunol Res. 2019 Dec;7(12):1984-1997. doi: 10.1158/2326-6066.CIR-19-0056. Epub 2019 Sep 20.


Depleting T regulatory cells by targeting intracellular Foxp3 with a TCR mimic antibody.

Dao T, Mun SS, Scott AC, Jarvis CA, Korontsvit T, Yang Z, Liu L, Klatt MG, Guerreiro M, Selvakumar A, Brea EJ, Oh C, Liu C, Scheinberg DA.

Oncoimmunology. 2019 Apr 15;8(7):1570778. doi: 10.1080/2162402X.2019.1570778. eCollection 2019.


A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens.

Chang AY, Dao T, Gejman RS, Jarvis CA, Scott A, Dubrovsky L, Mathias MD, Korontsvit T, Zakhaleva V, Curcio M, Hendrickson RC, Liu C, Scheinberg DA.

J Clin Invest. 2017 Sep 1;127(9):3557. doi: 10.1172/JCI96860. Epub 2017 Sep 1. No abstract available.


A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens.

Chang AY, Dao T, Gejman RS, Jarvis CA, Scott A, Dubrovsky L, Mathias MD, Korontsvit T, Zakhaleva V, Curcio M, Hendrickson RC, Liu C, Scheinberg DA.

J Clin Invest. 2017 Jun 30;127(7):2705-2718. doi: 10.1172/JCI92335. Epub 2017 Jun 19. Erratum in: J Clin Invest. 2017 Sep 1;127(9):3557.


An immunogenic WT1-derived peptide that induces T cell response in the context of HLA-A*02:01 and HLA-A*24:02 molecules.

Dao T, Korontsvit T, Zakhaleva V, Jarvis C, Mondello P, Oh C, Scheinberg DA.

Oncoimmunology. 2016 Dec 7;6(2):e1252895. doi: 10.1080/2162402X.2016.1252895. eCollection 2017.


Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1.

Dao T, Pankov D, Scott A, Korontsvit T, Zakhaleva V, Xu Y, Xiang J, Yan S, de Morais Guerreiro MD, Veomett N, Dubrovsky L, Curcio M, Doubrovina E, Ponomarev V, Liu C, O'Reilly RJ, Scheinberg DA.

Nat Biotechnol. 2015 Oct;33(10):1079-86. doi: 10.1038/nbt.3349. Epub 2015 Sep 21.


Therapeutic efficacy of an Fc-enhanced TCR-like antibody to the intracellular WT1 oncoprotein.

Veomett N, Dao T, Liu H, Xiang J, Pankov D, Dubrovsky L, Whitten JA, Park SM, Korontsvit T, Zakhaleva V, Casey E, Curcio M, Kharas MG, O'Reilly RJ, Liu C, Scheinberg DA.

Clin Cancer Res. 2014 Aug 1;20(15):4036-46. doi: 10.1158/1078-0432.CCR-13-2756. Epub 2014 May 21.


Targeting the intracellular WT1 oncogene product with a therapeutic human antibody.

Dao T, Yan S, Veomett N, Pankov D, Zhou L, Korontsvit T, Scott A, Whitten J, Maslak P, Casey E, Tan T, Liu H, Zakhaleva V, Curcio M, Doubrovina E, O'Reilly RJ, Liu C, Scheinberg DA.

Sci Transl Med. 2013 Mar 13;5(176):176ra33. doi: 10.1126/scitranslmed.3005661.


Single-walled carbon nanotubes deliver peptide antigen into dendritic cells and enhance IgG responses to tumor-associated antigens.

Villa CH, Dao T, Ahearn I, Fehrenbacher N, Casey E, Rey DA, Korontsvit T, Zakhaleva V, Batt CA, Philips MR, Scheinberg DA.

ACS Nano. 2011 Jul 26;5(7):5300-11. doi: 10.1021/nn200182x. Epub 2011 Jun 23.


WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer.

Krug LM, Dao T, Brown AB, Maslak P, Travis W, Bekele S, Korontsvit T, Zakhaleva V, Wolchok J, Yuan J, Li H, Tyson L, Scheinberg DA.

Cancer Immunol Immunother. 2010 Oct;59(10):1467-79. doi: 10.1007/s00262-010-0871-8. Epub 2010 Jun 8.


Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia.

Maslak PG, Dao T, Krug LM, Chanel S, Korontsvit T, Zakhaleva V, Zhang R, Wolchok JD, Yuan J, Pinilla-Ibarz J, Berman E, Weiss M, Jurcic J, Frattini MG, Scheinberg DA.

Blood. 2010 Jul 15;116(2):171-9. doi: 10.1182/blood-2009-10-250993. Epub 2010 Apr 16.


Identification of a human cyclin D1-derived peptide that induces human cytotoxic CD4 T cells.

Dao T, Korontsvit T, Zakhaleva V, Haro K, Packin J, Scheinberg DA.

PLoS One. 2009 Aug 25;4(8):e6730. doi: 10.1371/journal.pone.0006730.


Non-natural and photo-reactive amino acids as biochemical probes of immune function.

Gómez-Nuñez M, Haro KJ, Dao T, Chau D, Won A, Escobar-Alvarez S, Zakhaleva V, Korontsvit T, Gin DY, Scheinberg DA.

PLoS One. 2008;3(12):e3938. doi: 10.1371/journal.pone.0003938. Epub 2008 Dec 15.


A pilot vaccination trial of synthetic analog peptides derived from the BCR-ABL breakpoints in CML patients with minimal disease.

Maslak PG, Dao T, Gomez M, Chanel S, Packin J, Korontsvit T, Zakhaleva V, Pinilla-Ibarz J, Berman E, Scheinberg DA.

Leukemia. 2008 Aug;22(8):1613-6. doi: 10.1038/leu.2008.7. Epub 2008 Feb 7. No abstract available.


Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.

May RJ, Dao T, Pinilla-Ibarz J, Korontsvit T, Zakhaleva V, Zhang RH, Maslak P, Scheinberg DA.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4547-55. Erratum in: Clin Cancer Res. 2007 Sep 1;13(17):5226.


Improved human T-cell responses against synthetic HLA-0201 analog peptides derived from the WT1 oncoprotein.

Pinilla-Ibarz J, May RJ, Korontsvit T, Gomez M, Kappel B, Zakhaleva V, Zhang RH, Scheinberg DA.

Leukemia. 2006 Nov;20(11):2025-33. Epub 2006 Aug 31.


Natural killer cells license dendritic cell cross-presentation of B lymphoma cell--associated antigens.

Dao T, Gomez-Nunez M, Antczak C, Kappel B, Jaggi JS, Korontsvit T, Zakhaleva V, Scheinberg DA.

Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8763-72.


Synthetic peptide analogs derived from bcr/abl fusion proteins and the induction of heteroclitic human T-cell responses.

Pinilla-Ibarz J, Korontsvit T, Zakhaleva V, Roberts W, Scheinberg DA.

Haematologica. 2005 Oct;90(10):1324-32.


A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia.

Cathcart K, Pinilla-Ibarz J, Korontsvit T, Schwartz J, Zakhaleva V, Papadopoulos EB, Scheinberg DA.

Blood. 2004 Feb 1;103(3):1037-42. Epub 2003 Sep 22.


Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses.

Pinilla-Ibarz J, Cathcart K, Korontsvit T, Soignet S, Bocchia M, Caggiano J, Lai L, Jimenez J, Kolitz J, Scheinberg DA.

Blood. 2000 Mar 1;95(5):1781-7.


Modulation of p53, WAF1/p21 and BCL-2 expression during retinoic acid-induced differentiation of NB4 promyelocytic cells.

Bocchia M, Xu Q, Wesley U, Xu Y, Korontsvit T, Loganzo F, Albino AP, Scheinberg DA.

Leuk Res. 1997 May;21(5):439-47.


Specific human cellular immunity to bcr-abl oncogene-derived peptides.

Bocchia M, Korontsvit T, Xu Q, Mackinnon S, Yang SY, Sette A, Scheinberg DA.

Blood. 1996 May 1;87(9):3587-92.


Supplemental Content

Loading ...
Support Center